Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure

Leuk Lymphoma. 2004 Jul;45(7):1391-4. doi: 10.1080/10428190310001653736.

Abstract

We retrospectively evaluated the outcome of 94 consecutive elderly patients treated at our center for an aggressive lymphoma without a low-grade component. Median survival was 26 months and 5-year overall survival was 39% (27-50%). We then evaluated the outcome of patients refractory to or relapsing after CHOP or CHOP-like chemotherapy. Twenty patients were refractory to first-line therapy and only 1/20 is alive with active lymphoma. Eight patients achieved a partial response and only 3 maintained the partial response while the other 5 patients died. Only 2 of the 27 patients who relapsed after a first complete remission achieved a second sustained complete remission. This study suggests that conventional-dose second-line chemotherapy yields disappointing results in elderly patients with aggressive lymphomas.

Publication types

  • Review

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Disease Progression
  • Doxorubicin / administration & dosage
  • Doxorubicin / analogs & derivatives
  • Drug Evaluation
  • Drug Resistance, Neoplasm
  • Etoposide / administration & dosage
  • Female
  • Humans
  • Life Tables
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / mortality*
  • Male
  • Middle Aged
  • Prednisone / administration & dosage
  • Prognosis
  • Recurrence
  • Remission Induction
  • Retrospective Studies
  • Salvage Therapy* / statistics & numerical data
  • Survival Analysis
  • Treatment Outcome
  • Vincristine / administration & dosage

Substances

  • Cytarabine
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol
  • CHOP protocol, modified